EBUS-TBNA for Lung Cancer
Trial Summary
What is the purpose of this trial?
It is reported that more than 90,000 patients died of lung cancer and more than 20% of them were older than 80 years in North America. Therefore a less invasive but effective treatment is required for patients with lung cancer of advanced age, diminished pulmonary functions, and chronic diseases. Stereotactic body radiation therapy (SBRT) is an effective and well-tolerated treatment for early stage lung cancer in medically inoperable patients. On the other hand, accurate mediastinal and hilar lymph node staging is one of the most important factors that determine the outcome and indications for SBRT. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a novel, minimally invasive modality that enables the assessment of mediastinal and hilar lymph nodes with a high sensitivity. Accurate lymph node staging by EBUS-TBNA will allow opportunities for high-risk patients with lung cancer to undergo minimally invasive treatment.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are planning to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery, you may not be eligible for this trial.
What data supports the effectiveness of the treatment EBUS-TBNA for lung cancer?
EBUS-TBNA is a minimally invasive procedure that helps in diagnosing and staging lung cancer by improving the accuracy of identifying cancer spread to lymph nodes. It is particularly useful for non-small cell lung cancer and has shown potential in increasing the diagnostic yield compared to conventional methods.12345
Is EBUS-TBNA safe for humans?
Research Team
Kazuhiro Yasufuku, MD
Principal Investigator
UHN
Eligibility Criteria
This trial is for adults over 18 with confirmed non-small cell lung cancer who can't have surgery or chose not to. They should be in fair health (performance status 0-2), have early-stage T1-2 disease without distant metastasis, and need EBUS-TBNA staging before SBRT treatment. Pregnant women, those unfit for bronchoscopy, or planning other treatments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-Treatment Evaluation
Patients undergo CT and PET scans prior to EBUS-TBNA to determine operability and assess lymph nodes
EBUS-TBNA Procedure
Endobronchial ultrasound-guided transbronchial needle aspiration is performed to assess mediastinal and hilar lymph nodes
Treatment
Patients negative for mediastinal lymph node metastasis undergo stereotactic body radiotherapy (SBRT)
Follow-up
Participants are monitored for treatment outcomes and safety through clinical chart reviews
Treatment Details
Interventions
- EBUS-TBNA
EBUS-TBNA is already approved in European Union, United States, Japan for the following indications:
- Mediastinal and hilar lymph node staging for non-small cell lung cancer
- Mediastinal and hilar lymph node staging for non-small cell lung cancer
- Mediastinal and hilar lymph node staging for non-small cell lung cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor